TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Controlled Trial of Rehabilitation Following Critical Illness: A Short Term Feasibility and Follow-Up Pilot Study
Brief Summary: The principal research question to be answered by this study is whether an exercise based rehabilitative intervention following critical illness can generate improvements in exercise capacity and quality of life beyond current (usual) care. The investigators will also aim to demonstrate that such an intervention is both practical and cost-effective.


Options:
A: Arm Label: Early PT OT; Type: EXPERIMENTAL; Interventions: Procedure: early PT OT | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: early PT OT; Assigned to Arm(s): Early PT OT
B: N/A
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Pulmonary Rehabilitation | Intervention Type: OTHER; Name: Pulmonary Rehabilitation; Assigned to Arm(s): Intervention
D: Arm Label: ICU Recovery Manual & placebo supplement; Type: ACTIVE_COMPARATOR; Interventions: Other: Intensive Care Unit (ICU) Recovery Manual, Dietary Supplement: Placebo nutritional supplement | Arm Label: ICU recovery manual & amino acid (AA) supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Amino acid supplement, Other: Intensive Care Unit (ICU) Recovery Manual | Arm Label: PEPSE & placebo supplement; Type: EXPERIMENTAL; Interventions: Other: PEPSE, Other: Intensive Care Unit (ICU) Recovery Manual, Dietary Supplement: Placebo nutritional supplement | Arm Label: PEPSE & AA supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Amino acid supplement, Other: PEPSE, Other: Intensive Care Unit (ICU) Recovery Manual | Intervention Type: DIETARY_SUPPLEMENT; Name: Amino acid supplement; Assigned to Arm(s): ICU recovery manual & amino acid (AA) supplement, PEPSE & AA supplement | Intervention Type: OTHER; Name: PEPSE; Assigned to Arm(s): PEPSE & AA supplement, PEPSE & placebo supplement | Intervention Type: OTHER; Name: Intensive Care Unit (ICU) Recovery Manual; Assigned to Arm(s): ICU Recovery Manual & placebo supplement, ICU recovery manual & amino acid (AA) supplement, PEPSE & AA supplement, PEPSE & placebo supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo nutritional supplement; Assigned to Arm(s): ICU Recovery Manual & placebo supplement, PEPSE & placebo supplement

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Controlled Trial of Rehabilitation Following Critical Illness: A Short Term Feasibility and Follow-Up Pilot Study
Brief Summary: The principal research question to be answered by this study is whether an exercise based rehabilitative intervention following critical illness can generate improvements in exercise capacity and quality of life beyond current (usual) care. The investigators will also aim to demonstrate that such an intervention is both practical and cost-effective.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Pulmonary Rehabilitation | Intervention Type: OTHER; Name: Pulmonary Rehabilitation; Assigned to Arm(s): Intervention
B: Arm Label: Feet First; Type: EXPERIMENTAL; Interventions: Behavioral: Feet First | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Feet First; Assigned to Arm(s): Feet First
C: Arm Label: Specific rehabilitation program; Type: EXPERIMENTAL; Interventions: Behavioral: Specific rehabilitation program | Arm Label: Usual Care; Type: OTHER; Interventions: Behavioral: Specific rehabilitation program, Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Specific rehabilitation program; Assigned to Arm(s): Specific rehabilitation program, Usual Care | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Educational session to promote physical activity | Arm Label: 2; Type: OTHER; Interventions: Other: Minimal contact | Intervention Type: OTHER; Name: Educational session to promote physical activity; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Minimal contact; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AURELIA: A Multi-center, Open-label, Randomised, Two-arm Phase III Trial of the Effect on Progression Free Survival of Bevacizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Brief Summary: This randomized, open-label, 2-arm study will evaluate the efficacy and safety of Avastin added to chemotherapy versus chemotherapy alone in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer with disease progression within 6 months of platinum therapy. All patients will receive standard chemotherapy with either paclitaxel or topotecan or liposomal doxorubicin. Patients randomized to Arm 2 of the study will receive Avastin (10 mg/kg iv 2-weekly or 15 mg/kg iv 3-weekly) concomitantly. Anticipated time on study treatment is until disease progression. Patients will then receive standard of care, those in Arm 1 (chemotherapy only) may opt to receive Avastin (15 mg/kg iv 3-weekly). Target sample size is 100-500 individuals.


Options:
A: Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Arm Label: Chemotherapy + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: topotecan; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: AMG 386 Placebo, Drug: Carboplatin | Arm Label: AMG 386; Type: ACTIVE_COMPARATOR; Interventions: Drug: AMG 386, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): AMG 386 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): AMG 386, Placebo | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): AMG 386, Placebo
C: Arm Label: DOXIL + trabectedin; Type: EXPERIMENTAL; Interventions: Drug: Trabectedin, Drug: DOXIL, Drug: Dexamethasone | Arm Label: DOXIL; Type: ACTIVE_COMPARATOR; Interventions: Drug: DOXIL | Intervention Type: DRUG; Name: Trabectedin; Assigned to Arm(s): DOXIL + trabectedin | Intervention Type: DRUG; Name: DOXIL; Assigned to Arm(s): DOXIL, DOXIL + trabectedin | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): DOXIL + trabectedin
D: Arm Label: BIBF1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF1120 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BIBF1120; Assigned to Arm(s): BIBF1120 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH With Paricalcitol-centered Therapy vs. Cinacalcet Therapy With Low-dose Vitamin D in Hemodialysis Patients With Secondary Hyperparathyroidism
Brief Summary: Evaluates the effectiveness of on-label Paricalcitol versus Cinacalcet with Low-Dose Vitamin D.


Options:
A: Intervention Type: DRUG; Name: Cinacalcet HCl; Assigned to Arm(s): N/A
B: Arm Label: Cinacalcet; Type: EXPERIMENTAL; Interventions: Drug: Cinacalcet | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cinacalcet; Assigned to Arm(s): Cinacalcet | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: IV Paricalcitol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paricalcitol | Arm Label: Cinacalcet (at sites with IV paricalcitol); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cinacalcet | Arm Label: Oral paricalcitol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paricalcitol | Arm Label: Cinacalcet (at sites with oral paricalcitol); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cinacalcet | Intervention Type: DRUG; Name: Paricalcitol; Assigned to Arm(s): IV Paricalcitol, Oral paricalcitol | Intervention Type: DRUG; Name: Cinacalcet; Assigned to Arm(s): Cinacalcet (at sites with IV paricalcitol), Cinacalcet (at sites with oral paricalcitol)
D: Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: Other: Standard of care | Arm Label: Cinacalcet; Type: OTHER; Interventions: Drug: cinacalcet | Intervention Type: DRUG; Name: cinacalcet; Assigned to Arm(s): Cinacalcet | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Standard of care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: High Myopia - Partial Reduction Orthokeratology Study
Brief Summary: The purpose of this study is to evaluate and compare the eyeball elongation in high myopic children using partial correction orthokeratology and single-vision spectacles.


Options:
A: Arm Label: Orthokeratology lenses; Type: EXPERIMENTAL; Interventions: Device: Orthokeratology lenses | Arm Label: Single-vision spectacle lenses; Type: OTHER; Interventions: Device: Single-vision spectacle lenses | Intervention Type: DEVICE; Name: Orthokeratology lenses; Assigned to Arm(s): Orthokeratology lenses | Intervention Type: DEVICE; Name: Single-vision spectacle lenses; Assigned to Arm(s): Single-vision spectacle lenses
B: Intervention Type: DRUG; Name: 0.25 % atropine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: 0.5 % atropine; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: 0.25 % atropine+auricular acupoints; Assigned to Arm(s): N/A
C: Arm Label: auricular acupoint stimulation; Type: EXPERIMENTAL; Interventions: Drug: Atropine, Device: auricular acupoint stimulation | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine, auricular acupoint stimulation | Intervention Type: DEVICE; Name: auricular acupoint stimulation; Assigned to Arm(s): auricular acupoint stimulation
D: Arm Label: Progressive addition lenses (PALs); Type: ACTIVE_COMPARATOR; Interventions: Device: Progressive Addition Lenses (PALs) | Arm Label: Single vision lenses (SVLs); Type: ACTIVE_COMPARATOR; Interventions: Device: Single Vision Lenses (SVLs) | Intervention Type: DEVICE; Name: Progressive Addition Lenses (PALs); Assigned to Arm(s): Progressive addition lenses (PALs) | Intervention Type: DEVICE; Name: Single Vision Lenses (SVLs); Assigned to Arm(s): Single vision lenses (SVLs)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: High Myopia - Partial Reduction Orthokeratology Study
Brief Summary: The purpose of this study is to evaluate and compare the eyeball elongation in high myopic children using partial correction orthokeratology and single-vision spectacles.


Options:
A: Arm Label: Orthokeratology lenses; Type: EXPERIMENTAL; Interventions: Device: Orthokeratology lenses | Arm Label: Single-vision spectacle lenses; Type: OTHER; Interventions: Device: Single-vision spectacle lenses | Intervention Type: DEVICE; Name: Orthokeratology lenses; Assigned to Arm(s): Orthokeratology lenses | Intervention Type: DEVICE; Name: Single-vision spectacle lenses; Assigned to Arm(s): Single-vision spectacle lenses
B: Arm Label: Single vision spectacle lens; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Multiple-Segment spectacle lens; Type: EXPERIMENTAL; Interventions: Device: Multiple-Segment spectacle lens | Intervention Type: DEVICE; Name: Multiple-Segment spectacle lens; Assigned to Arm(s): Multiple-Segment spectacle lens
C: N/A
D: Arm Label: Bifocal spectacles; Type: ACTIVE_COMPARATOR; Interventions: Device: Bifocal spectacles | Arm Label: Prismatic bifocals; Type: ACTIVE_COMPARATOR; Interventions: Device: Prismatic bifocal spectacles | Arm Label: Single vision spectacles; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Bifocal spectacles; Assigned to Arm(s): Bifocal spectacles | Intervention Type: DEVICE; Name: Prismatic bifocal spectacles; Assigned to Arm(s): Prismatic bifocals

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users. A Double Blind, Placebo Controlled Trial
Brief Summary: Primary aim: Will varenicline be better than placebo to get long-term users of NRT to stop?

Secondary aim: To assess in details some side effects of varenicline i.e. nausea and abnormal dreams.


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: IQOS; Type: EXPERIMENTAL; Interventions: Device: IQOS | Arm Label: E-CIG; Type: ACTIVE_COMPARATOR; Interventions: Device: E-CIG | Intervention Type: DEVICE; Name: IQOS; Assigned to Arm(s): IQOS | Intervention Type: DEVICE; Name: E-CIG; Assigned to Arm(s): E-CIG
C: Arm Label: Chantix (varenicline); Type: EXPERIMENTAL; Interventions: Drug: Chantix | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix (varenicline) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: support and visits, Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: support and visits, Drug: placebo | Intervention Type: BEHAVIORAL; Name: support and visits; Assigned to Arm(s): placebo, varenicline | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users. A Double Blind, Placebo Controlled Trial
Brief Summary: Primary aim: Will varenicline be better than placebo to get long-term users of NRT to stop?

Secondary aim: To assess in details some side effects of varenicline i.e. nausea and abnormal dreams.


Options:
A: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: support and visits, Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: support and visits, Drug: placebo | Intervention Type: BEHAVIORAL; Name: support and visits; Assigned to Arm(s): placebo, varenicline | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Varenicline + Active Patch; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Drug: Varenicline | Arm Label: Varenicline + Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Varenicline + Active Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Patch, Varenicline + Placebo Patch
C: Arm Label: Placebo Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Placebo | Arm Label: Experimental: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Varenicline | Intervention Type: BEHAVIORAL; Name: Smoking cessation counseling; Assigned to Arm(s): Experimental: Varenicline, Placebo Control | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Control | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Experimental: Varenicline
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling and Nicotine replacement (CN) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling, Nicotine replacement and Bupropion (CNB) | Intervention Type: BEHAVIORAL; Name: Counseling and Nicotine replacement (CN); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Counseling, Nicotine replacement and Bupropion (CNB); Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users. A Double Blind, Placebo Controlled Trial
Brief Summary: Primary aim: Will varenicline be better than placebo to get long-term users of NRT to stop?

Secondary aim: To assess in details some side effects of varenicline i.e. nausea and abnormal dreams.


Options:
A: Arm Label: Healthy Control - Non-smoking; Type: OTHER; Interventions: Other: Biological Control | Arm Label: Healthy Control - Smoker; Type: OTHER; Interventions: Other: Biological Control | Arm Label: HIV Smoking Cessation Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline tartrate, Drug: Nicotine Replacement Therapy | Arm Label: Motivational Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interview | Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): HIV Smoking Cessation Arm | Intervention Type: DRUG; Name: Nicotine Replacement Therapy; Assigned to Arm(s): HIV Smoking Cessation Arm | Intervention Type: OTHER; Name: Biological Control; Assigned to Arm(s): Healthy Control - Non-smoking, Healthy Control - Smoker | Intervention Type: BEHAVIORAL; Name: Motivational Interview; Assigned to Arm(s): Motivational Intervention
B: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: support and visits, Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: support and visits, Drug: placebo | Intervention Type: BEHAVIORAL; Name: support and visits; Assigned to Arm(s): placebo, varenicline | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users. A Double Blind, Placebo Controlled Trial
Brief Summary: Primary aim: Will varenicline be better than placebo to get long-term users of NRT to stop?

Secondary aim: To assess in details some side effects of varenicline i.e. nausea and abnormal dreams.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: support and visits, Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: support and visits, Drug: placebo | Intervention Type: BEHAVIORAL; Name: support and visits; Assigned to Arm(s): placebo, varenicline | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: NRT arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy (NRT) | Arm Label: NRT and HIV Tailored Quit Smoking Counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy (NRT), Behavioral: HIV Tailored Quit Smoking Counseling | Arm Label: Varenicline (VR) Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Varenicline (VR) and HIV Tailored Quit Smoking Counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Behavioral: HIV Tailored Quit Smoking Counseling | Intervention Type: DRUG; Name: Nicotine Replacement Therapy (NRT); Assigned to Arm(s): NRT and HIV Tailored Quit Smoking Counseling, NRT arm | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline (VR) Arm, Varenicline (VR) and HIV Tailored Quit Smoking Counseling | Intervention Type: BEHAVIORAL; Name: HIV Tailored Quit Smoking Counseling; Assigned to Arm(s): NRT and HIV Tailored Quit Smoking Counseling, Varenicline (VR) and HIV Tailored Quit Smoking Counseling
D: Arm Label: Bupropion SR + Contingency Management; Type: EXPERIMENTAL; Interventions: Drug: Bupropion SR, Behavioral: Contingency Management | Arm Label: Placebo + Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Contingency Management, Other: Placebo | Arm Label: Bupropion SR + No Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo + No Contingency Management; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR + Contingency Management, Bupropion SR + No Contingency Management | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): Bupropion SR + Contingency Management, Placebo + Contingency Management | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo + Contingency Management, Placebo + No Contingency Management

Answer: B